세미나
Introduction to pancreatic cancer and pancreatic cancer research in Gastroenterology of SNUH
연사
2022. 10. 26 (수) 17:00
세미나개최일
Sang Hyub Lee, M.D., Ph.D. (Seoul National University Hospital, Seoul National University College of Medicine)
Author
박헌주
Date
2022-10-17
Views
395
Pancreatic cancer ise of the leading cause of cancer related death, the 5-year overall survival rate of patients isly 11%. It is expected to be the second cause of cancer death in the next decade. The Department of Gastroenterology at Seoul National University Hospital is in charge of the entire process from diagnosis to treatment of pancreatic cancer.
Among them, endoscopic procedures are main roles of our department in charge of the entire process from diagnosis to treatment of pancreatic cancer. Those are used for the diagnosis and palliative therapy of pancreatic cancer. Endoscopy as a medical discipline continues to evolve and is becoming increasingly therapeutic in nature. Minimally invasive endoscopic intervention now is effective in a wide variety of disorders. Among them, the role of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) continues to mature. Endoscopic retrograde cholangiopancreatography (ERCP) has evolved from a primarily diagnostic to palliative therapeutic procedure in pancreatic cancer. The development of endoscopic ultrasound (EUS) technology has expanded greatly the potential utility of endoscopy as a diagnostic and a therapeutic modality. Further thorough examination for pancreas was possible by EUS with high diagnostic accuracy. EUS guided fine needle aspiration and biopsy has made possible to perform less invasive histologic confirmation of pancreatic cancer.
Chemotherapy is the main role of our department, also. Although surgery is the potentially curative treatment for pancreatic adenocarcinoma,ly 10-20% of patients with pancreatic cancer have resectable disease at the time of diagnosis. Approximately other 80% of patients with pancreatic cancer have unresectable, and standard treatment of metastatic and locally advanced pancreatic cancer patients is systemic chemotherapy. However, since it is essential to manage pancreatic cancer with multiple departments such as surgery, radiology, and radiationcology, we are cooperating with several departments.
Today, we would like to briefly introduce the general information about pancreatic cancer, the pancreatic cancer treatment conducted by our department. Where appropriate, future research directions are discussed in each section, and related research.
Among them, endoscopic procedures are main roles of our department in charge of the entire process from diagnosis to treatment of pancreatic cancer. Those are used for the diagnosis and palliative therapy of pancreatic cancer. Endoscopy as a medical discipline continues to evolve and is becoming increasingly therapeutic in nature. Minimally invasive endoscopic intervention now is effective in a wide variety of disorders. Among them, the role of therapeutic endoscopic retrograde cholangiopancreatography (ERCP) continues to mature. Endoscopic retrograde cholangiopancreatography (ERCP) has evolved from a primarily diagnostic to palliative therapeutic procedure in pancreatic cancer. The development of endoscopic ultrasound (EUS) technology has expanded greatly the potential utility of endoscopy as a diagnostic and a therapeutic modality. Further thorough examination for pancreas was possible by EUS with high diagnostic accuracy. EUS guided fine needle aspiration and biopsy has made possible to perform less invasive histologic confirmation of pancreatic cancer.
Chemotherapy is the main role of our department, also. Although surgery is the potentially curative treatment for pancreatic adenocarcinoma,ly 10-20% of patients with pancreatic cancer have resectable disease at the time of diagnosis. Approximately other 80% of patients with pancreatic cancer have unresectable, and standard treatment of metastatic and locally advanced pancreatic cancer patients is systemic chemotherapy. However, since it is essential to manage pancreatic cancer with multiple departments such as surgery, radiology, and radiationcology, we are cooperating with several departments.
Today, we would like to briefly introduce the general information about pancreatic cancer, the pancreatic cancer treatment conducted by our department. Where appropriate, future research directions are discussed in each section, and related research.
